BioCentury
ARTICLE | Clinical News

Genentech's lampalizumab misses in Phase III for geographic atrophy due to AMD

October 20, 2017 12:30 AM UTC

In September, the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported data from the Phase III Spectri (GX29185) trial in about 975 patients with geographic atrophy (GA) due to age-related macular degeneration (AMD) showing that intravitreal lampalizumab (FCFD4514S, RG7417) missed the primary endpoint of reducing mean GA lesion area from baseline to week 48 as measured by fundus autofluorescence (FAF) vs. sham control.

Patients received sham injections or 10 mg intravitreal lampalizumab every 4 or 6 weeks. The double-blind, international trial's secondary endpoints include the change from baseline in best corrected visual acuity (BCVA) as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart at week 96 and the proportion of patients with <15 letters lost in BCVA compared to baseline at week 96...

BCIQ Company Profiles

Genentech Inc.

Roche